Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term immunogenicity extension of a bivalent HPV (16/18) vaccine in healthy females aged 9–30 years
CTR20243243Phase 4Active
- Sponsor
- Yuxi Zerun Biotechnology Co., Ltd.
- Start
- Aug 2024
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine in Cervical Cancer (CC), cervical intraepithelial neoplasia (CIN), cervical adenocarcinoma, sponsored by Yuxi Zerun Biotechnology Co., Ltd.. Started Aug 2024; status: active.
02
Drugs
Human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine
03
Conditions
Cervical Cancer (CC)cervical intraepithelial neoplasia (CIN)cervical adenocarcinoma
Beyond the preview
Go deeper on CTR20243243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243243.